Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

This study has been completed.
Susan G. Komen Breast Cancer Foundation
Information provided by:
Stanford University Identifier:
First received: September 12, 2005
Last updated: July 16, 2010
Last verified: July 2010
The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive iodine entering breast cancer cells, how long your cancer retains the agent as well as how much is taken up by other organs, particularly the thyroid gland.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Resource links provided by NLM:

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA
Archival tissue blocks and blood

Estimated Enrollment: 25
Study Start Date: November 2000
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Detailed Description:
To demonstrate iodide uptake capacity of breast cancer metastases by imaging women with iodide radioisotope (123I) and calculating potential ablative dose of radioactive iodide (131I).

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eligibility criteria include histological proof of invasive breast cancer and current radiological evidence of metastatic disease.

Inclusion Criteria:- Only women diagnosed with breast cancer

  • 18 years of age or older
  • From whom informed consent can be obtained
  • Patient is able to provide a fluid (e.g. cyst fluid)
  • Patient with blood test that shows protein may allow iodide to accumulate in breast tissue
  • Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours

Exclusion Criteria:- Males

- Children

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00185809

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Susan G. Komen Breast Cancer Foundation
Principal Investigator: Irene L. Wapnir Stanford University
  More Information

Responsible Party: Irene L. Wapnir, Stanford University School of Medicine Identifier: NCT00185809     History of Changes
Other Study ID Numbers: BRSMTS0002
Study First Received: September 12, 2005
Last Updated: July 16, 2010

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on May 25, 2017